首页> 外文期刊>Thoracic cancer. >Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways
【24h】

Scutellarin suppresses proliferation and promotes apoptosis in A549 lung adenocarcinoma cells via AKT/mTOR/4EBP1 and STAT3 pathways

机译:Scutellarin通过Akt / mtor / 4ebp1和Stat3途径抑制A549肺腺癌细胞中的增殖并促进细胞凋亡

获取原文
       

摘要

Scutellarin (SCU), a flavonoid isolated from Erigeron breviscapus (Vant.) Hand.-Mazz., increases autophagy and apoptosis in the adenocarcinoma A549 cell line, which is resistant to cisplatin. However, whether SCU alone has antitumor activity against non-small cell lung cancer (NSCLC) is unknown. Cell Counting Kit-8, flow cytometry, colony formation, Hoechst 33258 staining, and Western blot analyses were used to examine the proliferation and apoptosis of A549 cells treated with SCU and the possible molecular mechanisms. The cell viability assay indicated that SCU markedly suppressed the proliferation of A549 cells in concentration and time-dependent manners. SCU caused significant G0/G1 phase arrest and apoptosis, as evidenced by flow cytometric analyses, Hoechst 33258 staining, and Western blot analyses of cyclin D1, cyclin E, BCL-2, cleaved-caspase-3, and BAX. Furthermore, SCU treatment reduced the level of pan-AKT, phosphorylated (p)-mTOR, mTOR, BCL-XL, STAT3, and p-STAT3, and increased the level of 4EBP1. SCU can suppress proliferation and promote apoptosis in A549 cells through AKT/mTOR/4EBP1 and STAT3 pathways. This suggests that SCU may be developed into a promising antitumor agent for treating NSCLC. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译:Scutellarin(SCU),一种从Erigeron Breviscapus(vant。)的黄酮类化合物的手。-mazz。,增加腺癌A549细胞系中的自噬和凋亡,这是对顺铂的抗性。然而,单独的SCU是否具有对非小细胞肺癌(NSCLC)的抗肿瘤活性是未知的。用于细胞计数试剂盒-8,流式细胞术,菌落形成,Hoechst 33258染色和蛋白质印迹分析来检查用SCU处理的A549细胞的增殖和凋亡和可能的分子机制。细胞活力测定表明,SCU显着抑制了浓度和时间依赖的举止的A549细胞的增殖。 SCU引起了显着的G0 / G1相滞和凋亡,通过流式细胞术分析,Hoechst 33258染色和细胞周期蛋白D1,Cyclin E,Bcl-2,切割 - caspase-3和Bax的蛋白质印迹分析证明。此外,SCU治疗降低了Pan-AKT,磷酸化(P)-MTOR,MTOR,BCL-XL,STAT3和P-STAT3的水平,并增加了4EBP1的水平。 SCU可以通过AKT / MTOR / 4EBP1和Stat3途径抑制A549细胞中的增殖和促进凋亡。这表明SCU可以被开发成有望的抗肿瘤剂用于治疗NSCLC。 ? 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号